|
1
|
Rini BI, Campbell SC and Escudier B: Renal
cell carcinoma. Lancet. 373:1119–1132. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gupta K, Miller JD, Li JZ, Russell MW and
Charbonneau C: Epidemiologic and socioeconomic burden of metastatic
renal cell carcinoma (mRCC): A literature review. Cancer Treat Rev.
34:193–205. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hollingsworth JM, Miller DC, Daignault S
and Hollenbeck BK: Five-year survival after surgical treatment for
kidney cancer: A population-based competing risk analysis. Cancer.
109:1763–1768. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ljungberg B, Bensalah K, Canfield S,
Dabestani S, Hofmann F, Hora M, Kuczyk MA, Lam T, Marconi L,
Merseburger AS, et al: EAU guidelines on renal cell carcinoma: 2014
update. Eur Urol. 67:913–924. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
LeRoy G, Orphanides G, Lane WS and
Reinberg D: Requirement of RSF and FACT for transcription of
chromatin templates in vitro. Science. 282:1900–1904. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Loyola A, Huang JY, LeRoy G, Hu S, Wang
YH, Donnelly RJ, Lane WS, Lee SC and Reinberg D: Functional
analysis of the subunits of the chromatin assembly factor RSF. Mol
Cell Biol. 23:6759–6768. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ho L and Crabtree GR: Chromatin
remodelling during development. Nature. 463:474–484. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mao TL, Hsu CY, Yen MJ, Gilks B, Sheu JJ,
Gabrielson E, Vang R, Cope L, Kurman RJ, Wang TL and Shih IeM:
Expression of Rsf-1, a chromatin-remodeling gene, in ovarian and
breast carcinoma. Hum Pathol. 37:1169–1175. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yang YI, Ahn JH, Lee KT, Shih IeM and Choi
JH: RSF1 is a positive regulator of NF-κB-induced gene expression
required for ovarian cancer chemoresistance. Cancer Res.
74:2258–2269. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhao XC, An P, Wu XY, Zhang LM, Long B,
Tian Y, Chi XY and Tong DY: Overexpression of hSNF2H in glioma
promotes cell proliferation, invasion, and chemoresistance through
its interaction with Rsf-1. Tumour Biol. 37:7203–7212. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sanchez-Garcia F, Villagrasa P, Matsui J,
Kotliar D, Castro V, Akavia UD, Chen BJ, Saucedo-Cuevas L, Barrueco
Rodriguez R, Llobet-Navas D, et al: Integration of genomic data
enables selective discovery of breast cancer drivers. Cell.
159:1461–1475. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cheng CK, Chow LW, Loo WT, Chan TK and
Chan V: The cell cycle checkpoint gene Rad9 is a novel oncogene
activated by 11q13 amplification and DNA methylation in breast
cancer. Cancer Res. 65:8646–8654. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fang FM, Li CF, Huang HY, Lai MT, Chen CM,
Chiu IW, Wang TL, Tsai FJ, Shih IeM and Sheu JJ: Overexpression of
a chromatin remodeling factor, RSF-1/HBXAP, correlates with
aggressive oral squamous cell carcinoma. Am J Pathol.
178:2407–2415. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang X, Fu L, Xue D, Zhang X, Hao F, Xie
L, He J, Gai J, Liu Y, Xu H, et al: Overexpression of Rsf-1
correlates with poor survival and promotes invasion in non-small
cell lung cancer. Virchows Arch. 470:553–560. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shih IeM, Sheu JJ, Santillan A, Nakayama
K, Yen MJ, Bristow RE, Vang R, Parmigiani G, Kurman RJ, Trope CG,
et al: Amplification of a chromatin remodeling gene, Rsf-1/HBXAP,
in ovarian carcinoma. Proc Natl Acad Sci USA. 102:14004–14009.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li Q, Dong Q and Wang E: Rsf-1 is
overexpressed in non-small cell lung cancers and regulates cyclinD1
expression and ERK activity. Biochem Biophys Res Commun. 420:6–10.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li H, Zhang Y, Zhang Y, Bai X, Peng Y and
He P: Rsf-1 overexpression in human prostate cancer, implication as
a prognostic marker. Tumour Biol. 35:5771–5776. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xie C, Fu L, Xie L, Liu N and Li Q: Rsf-1
overexpression serves as a prognostic marker in human
hepatocellular carcinoma. Tumour Biol. 35:7595–7601. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
O'Sullivan GC, Tangney M, Casey G, Ambrose
M, Houston A and Barry OP: Modulation of p21-activated kinase 1
alters the behavior of renal cell carcinoma. Int J Cancer.
121:1930–1940. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Meng ZW, Pan W, Hong HJ, Chen JZ and Chen
YL: Modified staging classification for intrahepatic
cholangiocarcinoma based on the sixth and seventh editions of the
AJCC/UICC TNM staging systems. Medicine (Baltimore). 96:e78912017.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Davidson B, Trope' CG, Wang TL and Shih
IeM: Expression of the chromatin remodeling factor Rsf-1 is
upregulated in ovarian carcinoma effusions and predicts poor
survival. Gynecol Oncol. 103:814–819. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Roberts CW and Orkin SH: The SWI/SNF
complex-chromatin and cancer. Nat Rev Cancer. 4:133–142. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Choi JH, Sheu JJ, Guan B, Jinawath N,
Markowski P, Wang TL and Shih IeM: Functional analysis of 11q13.5
amplicon identifies Rsf-1 (HBXAP) as a gene involved in paclitaxel
resistance in ovarian cancer. Cancer Res. 69:1407–1415. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Brown LA, Irving J, Parker R, Kim H, Press
JZ, Longacre TA, Chia S, Magliocco A, Makretsov N, Gilks B, et al:
Amplification of EMSY, a novel oncogene on 11q13, in high grade
ovarian surface epithelial carcinomas. Gynecol Oncol. 100:264–270.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hennessy BT, Nanjundan M, Cheng KW, Nolden
L and Mills GB: Identification of remodeling and spacing factor 1
(rsf-1, HBXAP) at chromosome 11q13 as a putative oncogene in
ovarian cancer. Eur J Hum Genet. 14:381–383. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bostner J, Ahnström WM, Fornander T, Skoog
L, Nordenskjöld B and Stål O: Amplification of CCND1 and PAK1 as
predictors of recurrence and tamoxifen resistance in postmenopausal
breast cancer. Oncogene. 26:6997–7005. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Borg A, Tandon AK, Sigurdsson H, Clark GM,
Fernö M, Fuqua SA, Killander D and McGuire WL: HER-2/neu
amplification predicts poor survival in node-positive breast
cancer. Cancer Res. 50:4332–4337. 1990.PubMed/NCBI
|
|
28
|
Rubie H, Hartmann O, Michon J, Frappaz D,
Coze C, Chastagner P, Baranzelli MC, Plantaz D, Avet-Loiseau H,
Bénard J, et al: N-Myc gene amplification is a major prognostic
factor in localized neuroblastoma: results of the French NBL 90
study. Neuroblastoma Study Group of the Société Francaise
d'Oncologie Pédiatrique. J Clin Oncol. 15:1171–1182. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shamay M, Barak O and Shaul Y: HBXAP, a
novel PHD-finger protein, possesses transcription repression
activity. Genomics. 79:523–529. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sheu JJ, Choi JH, Guan B, Tsai FJ, Hua CH,
Lai MT, Wang TL and Shih IeM: Rsf-1, a chromatin remodelling
protein, interacts with cyclin E1 and promotes tumour development.
J Pathol. 229:559–568. 2013. View Article : Google Scholar : PubMed/NCBI
|
